Martin Brunovský
MUDr. Martin Brunovský, Ph.D., Head of the Clinical Research Program and senior researcher at the National Institute of Mental Health; lecturer at the Third Faculty of Medicine, Charles University
Data updated
Research Footprint
Martin Brunovský appears in 9 tracked papers (2012–2026), most studied alongside Psilocybin, Placebo and 2C-X, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.
Most-cited paper: Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in rats (74 citations).
Frequent co-authors: Tomáš Páleníček, František Tylš and Michaela Viktorinová.
Background & Research
Martin Brunovský is a Czech physician-scientist specializing in neurophysiology, quantitative EEG, and clinical psychopharmacology. He has worked at the National Institute of Mental Health in Czechia and at Charles University, where his research has included the effects of psilocybin, ketamine, and other psychoactive substances on brain function and psychiatric symptoms. His profile also notes involvement in the therapeutic potential of psychedelics and prediction of treatment response using neuromonitoring methods.
Key Impact
He is a key Czech clinical and EEG researcher whose work includes psychedelic, ketamine, and psychopharmacology studies relevant to translational psychiatry.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Martin Brunovský is associated with.